Guru P. Sonpavde, MD

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Guru P. Sonpavde, MD, discusses the AMBASSADOR trial of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma.

Guru P. Sonpavde, MD, discusses the implications of treatment with the NIAGARA trial regimen in cisplatin-eligible muscle-invasive bladder cancer.

Guru P. Sonpavde, MD, discusses initial data from a phase 1/2 trial of sacituzumab govitecan plus ipilimumab and nivolumab in metastatic urothelial cancer.

Dr. Sonpavde discusses the efficacy and safety findings from this randomized, open-label trial enrolling patients with advanced or metastatic urothelial carcinoma who had not received prior systemic chemotherapy.

Guru P. Sonpavde, MD, discusses the significance of data from the phase 3 CheckMate 901 trial of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma.

Guru P. Sonpavde, MD, discusses the importance of utilizing precision medicine in bladder cancer, and highlights the rationales and designs of the ongoing phase 3 EV-302 and AMBASSADOR trials.

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Guru P. Sonpavde, MD, discusses results from the phase 3 SWOG S1011 trial conducted in patients with muscle-invasive bladder cancer.

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Guru P. Sonpavde, MD, discusses the safety profile of erdafitinib, which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Guru P. Sonpavde, MD, discusses current neoadjuvant immunotherapy options in bladder cancer based on cisplatin eligibility status.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses emerging immunotherapy approaches in bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the biggest challenges in the field of bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses key data with immunotherapy in metastatic bladder cancer.